First Online: 9 December 2019
Compliance with Ethical Standards
: Dr. Brummett reported holding a patent for peripheral perineural dexmedetomidine licensed to the University of Michigan, being a consultant for Recro Pharma and Heron Therapeutics, and receiving research funding from Neuros Medical. All remaining authors declare that they do not have a conflict of interest.
: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, and approval of the manuscript and decision to submit the manuscript for publication.
Free to read: This content has been made available to all.